PPD Enhances Central Lab Data Capabilities Via Preclarus

Clients and Investigator Sites Benefit from Improved Processes and Better Data Access

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) is expanding Preclarus^®, its award-winning clinical data platform, to include a comprehensive set of data solutions that supports the company’s central lab operations. These changes will enable study sites to access clean central lab data in real time, improve inventory management and order tracking, facilitate patient management and safety, and establish complete chain of custody for samples. The goal of these enhancements is to increase the efficiency and effectiveness of managing central lab data for PPD’s clients.

“Preclarus offers our clients an unprecedented view of central laboratory data that support their clinical trials”

With the expansion of the Preclarus brand, PPD^® Laboratories is introducing the new Preclarus investigator site portal to support clinical trial sites. This portal is a key enhancement for PPD Laboratories’ clients because it builds upon the company’s current capabilities to provide sites with new tools and options to access clinical trial data and help better manage their patients. The company’s newly named Preclarus central lab database will continue to support the company’s central lab operations and project teams with real-time, studywide lab results, project status and site metrics.

“Preclarus offers our clients an unprecedented view of central laboratory data that support their clinical trials,” explains David Johnston, Ph.D., executive vice president of PPD Laboratories. “With its real-time access to study details, patient data and laboratory results, Preclarus drives informed decision-making and increased efficiency for PPD Laboratories and its clients.”

Preclarus is PPD’s comprehensive data solution that consolidates and standardizes data from multiple sources to give PPD teams and clients transparent, real-time access to clinical trial operations and patient data, which can be visualized on interactive dashboards. Coupled with sophisticated analytics that enable innovative research approaches, Preclarus provides the transparent reporting and analytic capabilities needed to turn data into actionable intelligence.

The new central lab portal is designed to make it easier for investigational sites to support PPD clinical trials. The reports and tools within the Preclarus investigator site portal simplify every process, including adding patients to the trial, ordering sample collection kits, reviewing laboratory results, managing patients and critical values, and accessioning and shipping samples to PPD. The new portal also provides on-site biorepository tools to help clients manage samples at their site and track them to their final destinations.

PPD Laboratories combines world-class scientific expertise with state-of-the art technologies supported by a commitment to exceptional quality. From early development through late stage research, clients benefit from comprehensive lab services spanning bioanalytical, vaccine sciences, GMP, central lab testing and biomarkers.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 14,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development to deliver life-changing therapies that improve health. For more information, visit www.ppdi.com.

PPD Forward-Looking Statement

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s enhanced central lab data solutions, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; rapid technological advances that make our services or capabilities less competitive; compliance with drug development regulations; changes in the regulation of the drug development process; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; risks associated with and dependence on strategic relationships; actual operating performance; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.